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Abstract
The cytotoxic T-lymphocyte antigen 4 (CTLA-4) gene is a negative regulator of T-lymphocyte activation and proliferation. 
Single nucleotide polymorphisms (SNPs) occurring on the CTLA-4 gene can modify the ability to control the proliferation of 
T-lymphocytes, thereby impacting the clearance of hepatitis B (HBV) and hepatitis C (HCV) virus infections. The −319C/T and 
+49A/G SNPs of CTLA-4 gene have been associated with autoimmune disorders and liver infections. Studies show that the 
+49G allele confers susceptibility to HBV and HCV infections in chronic disease (without cirrhosis), associates with the risk 
of chronic HCV infection in males, confers protective effect against the development of hepatocellular carcinoma, and favors 
viral elimination. Furthermore, the +49G allele alone or in haplotype with the −319C favors chronic infection with genotype 3 
HCV, has an inverse association with HCV genotype 1, and decreases viral load in chronic hepatitis C associated with sustained 
virological response (SVR). These findings support an important role of the SNPs of CTLA-4 gene in viral hepatitis; however, 
the mechanisms by which they influence immune response against viral infections are not fully understood. This review gives an 
overview of the current understanding of the association between CTLA4 SNPs and HBV/HCV infections.
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Chronic viral hepatitis is most commonly caused by hepa-
titis B (HBV) or hepatitis C (HCV) viruses. Chronic in-
fection is defined as a measurable viral load for more than 
6 months (1). An estimated 700,000 people die each year due 
to complications of chronic HCV and HBV infections such 
as cirrhosis and hepatocellular carcinoma (HCC) (2). HCV 
infection affects approximately 180 million people worldwide 
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and 75% of infected patients with acute disease progress to 
chronic infection (3–5). Approximately 400 million people 
are chronic HBV carriers. It is estimated that 5–10% of in-
dividuals infected are unable to eliminate the virus; of these, 
15–40% will develop cirrhosis or HCC (6–8). Both HBV and 
HCV have a similar natural history but with different propen-
sities for chronic complications. This difference may be due to 
an imbalance between genetic factors, and viral, environmen-
tal, and host components (9). Interestingly, HBV and HCV 
do not directly cause hepatocellular damage. The interaction 
between the virus and the immune response of the host is 
responsible for liver damage and the clinical manifestations 
of disease (10, 11). This demonstrates the importance of the 
immune system in determining how the body will respond 
to these pathogens. This review aims to discuss the results 
of research evaluating how single nucleotide polymorphisms 
(SNPs) in CTLA-4 gene may affect the course of HBV and 
HCV infections through their role in immune function.
CTLA-4 Immune Response against Viral 
Infections
Immunity against viral infections is determined through a 
variety of specific and nonspecific mechanisms. The predom-
inant immune response is through T-lymphocyte activation. 
Although the activated T-lymphocytes play an important 
role in the control of HBV and HCV infections, they also 
contribute to liver damage. T-lymphocytes recognize infected 
cells and respond through cytokine release and coordinated 
lysis of the infected cells (12). When the immune system 
fails to wholly eradicate an infection, immunomodulatory 
pathways are activated to minimize the extent of immune-
mediated tissue damage (13). Inappropriate induction of 
T-lymphocytes to recognize self-antigens at this stage can 
lead to autoimmune- driven damage.
The activation and function of T-lymphocytes in the im-
mune response depends on two signals. In the first signal, 
the HCV and HBV antigens are processed and presented by 
major histocompatibility complex (MHC) to T-cell receptor 
(TCR). This signal in isolation does not cause activation of 
the T-lymphocytes and requires costimulatory signals (14). 
The well-characterized costimulatory signal is the interaction 
between CD28 receptor on the surface of T-lymphocytes, 
and CD80 and CD86 ligands on the antigen-presenting cell 
(APC). This interaction triggers a biochemical cascade of 
signals such as IL-2 production, induction of antiapoptotic 
protein Bcl-xL, and cell-cycle progression, which are neces-
sary for the clonal expansion of T-cell populations (15, 16). 
CD28 is constitutively expressed on the surface of T-cells 
and  provides a costimulatory signal rapidly following T-lym-
phocyte binding to the APC (17), promoting the immune re-
sponse against HBV and HCV infections.
CTLA-4, another receptor structurally similar to CD28, 
also binds the CD80 and CD86 ligands with greater avidity 
than CD28. CTLA-4 can inhibit the activation of T-cells, in 
competition with CD28, and subsequently inhibit the co-
stimulatory effect of CD28. The CTLA-4 gene is encoded 
in human chromosome 2q33 and is made up of four exons 
and three introns (18). It is a member of the immunoglobu-
lin superfamily and is a costimulatory molecule expressed in 
activated T-cells (19). The CTLA-4 is a negative regulator of 
T-cell activation and proliferation through mechanisms such 
as reducing interleukin 2 (IL-2) and IL-2 receptor (IL-2R) 
expression, promoting G1 cell-cycle arrest of T-lympho-
cytes, and inducing FAS-independent apoptosis of activated 
T-lymphocytes (20, 21). Previous studies have reported that 
mice deficient of CTLA-4 develop lymphoproliferative dis-
orders and die from multiorgan failure and cytokine storm, 
suggesting the indispensable immunoregulatory role of 
CTLA-4 (22, 23). CTLA-4 is not constitutively expressed 
in resting T-lymphocytes. Upon TCR stimulation, CTLA-4 
 expression is induced, peaking 48–72 h following stimulation 
(24). A greater stimulation of T-cells induces greater levels of 
membrane-localized CTLA-4 expression (19). The increase 
in the expression of CD28 occurs during the activation of the 
T-lymphocytes; this effect induces the expression of CTLA-4 
and increases the stability of CTLA-4 mRNA (25, 26). After 
T-cell activation, CTLA-4 is endocytosed (19) in order to 
maintain a fast T-cell activation response. The interaction be-
tween T-lymphocytes, costimulatory molecules, and the effect 
of CTLA-4 SNPs is shown in Figure 1. 
CTLA-4 SNPs in HBV/HCV Infection
SNPs in cytokine and receptor genes (27) may be playing an 
important role in the outcome of HBV and HCV infections. 
More than 10 million polymorphisms in the human genome 
have been identified, some with the potential to influence the 
development of disease (28). In the CTLA-4 gene, SNPs have 
been reported at positions −1722, −1661, −319, +49, and 
CT60 (29). However, the most studied CTLA-4 SNPs in pa-
tients infected with HCV and HBV are −319 C/T (rs5742909) 
and +49 A/G (rs231775) (30–34). Studies in patients with 
HBV- and HCV-associated chronic liver disease (CLD) have 
reported differences in the allelic and genotypic frequencies of 
the −319 C/T and +49 A/G polymorphisms (Tables 1 and 2).
The −319 C/T SNP is named in many studies as −318 C/T; 
however, in the GenBank SNP database, it is described as 
−319 C/T (rs5742909) (35). We therefore consider the correct 
form as −319 C/T. The functional significance of −319 C/T 
CTLA-4 SNP in the promoter region it is not well defined; 
however, studies suggest participation in the binding of cis
-acting elements to the promoter (NF-1 and c/EBP beta), 
thus affecting the gene activity (36, 37). The presence of the 
−319T allele of −319 C/T SNP is associated with greater pro-
moter activity than the −319C allele, contributing to a greater 
expression of the CTLA-4 gene, representing a mechanism 
to inhibit the exaggerated cellular immune response (38) and 
contribute to hepatocellular damage in HBV and HCV infec-
tions (Figure 1A) (30, 39–42). The −319T allele is associated 
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Table 1. Allelic and genotypic frequencies of −319 C/T SNP in HBV/HCV infected patients and control subjects
−319 C/T  
Population, n = total
Genotype C allelen 
n (%) 
T allele  
n (%)C/C n (%) C/T n (%) T/T n (%)
Mexican
Control, n = 215 193 (89.8) 21 (9.7) 1 (0.5) 407 (94.6) 23 (5.4)
Enciso-Vargas et al. (30)
HCV, n = 205 183 (89.3) 22 (10.7) 0 (0) 388 (95.0) 22 (5.0)
Brazilian
Control, n = 183 152 (83.1) 31 (16.9) 0 (0) 335 (91.5) 31 (8.5)
Danilovic et al. (39)
HCV, n = 112 92 (82.1) 19 (17.0) 1 (0.9) 203 (90.6) 21 (9.4)
Iranian
Control, n = 65 55 (48.61) 9 (13.84) 1 (1.53) 119 (91.54) 11 (8.46)
Sepahi et al. (42)
HCV, n = 65 55 (48.61) 10 (15.38) 0 (0) 120 (92.30) 10 (7.70)
Iranian
Control, n = 150 134 (89.3) 10 (6.7) 6 (4.0) 278 (92.6) 22 (7.4) Mohammad Alizadeh 
et al. (59)HBV, n = 51 41 (80.4) 10 (19.6) 0 (0.0) 92 (90.2) 10 (9.8)
Values are presented in frequencies (%) and genotypes and alleles in number (n). Total alleles were determined considering that each homozy-
gote would contribute two copies of  the allele toward the total fraction, while each heterozygote would only contribute one copy toward the 
total fraction.
Figure 1. Function of  −319 C/T and +49 A/G SNPs in the immune response against HBV/HCV infection. (A) −319 C/T 
SNP in the immune response against HBV/HCV Infection; (B) + 49A/G SNP in the immune response against HBV/HCV 
infection.
with the likelihood of HBV persistence and susceptibility to 
progression of chronic liver damage, which is consistent with 
its emerging role in the T-regulatory cells in the pathogenesis 
of disease (31, 43). Conversely, some studies report that the 
−319 C/T SNP was underrepresented in patients with chronic 
HBV infection compared with healthy controls, and that it 
was not associated with autoimmune liver disease (33). In 
addition, these SNPs have been associated with the risk of 
developing B-cell non-Hodgkin lymphoma in patients with 
HCV and various autoimmune disorders (44–48). Few stud-
ies have documented the CTLA-4 SNPs in HCV infection, as 
most evaluate HBV infection and autoimmune diseases, in 
particular the +49 A/G SNP.
A transition of the +49A allele by the +49G allele in exon 1 
causes an amino acid change from threonine to alanine in the 
CTLA-4 protein. This change is associated with a reduction 
in CTLA-4 mRNA, increased T-cell activation, and instances 
of autoimmune disorders (49, 50). The presence of the +49G 
allele in the +49 A/G SNP favors inefficient glycosylation in 
the sequence of the leader peptide of CTLA-4, altering the 
process in the endoplasmic reticulum resulting in the reduced 
expression of the molecule on the cell surface (Figure 1B) (51). 
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Table 2. Allelic and genotypic frequencies of +49A/G SNP in HCV/HBV infected patients and control subjects
+49 A/G  
Population, n = total
Genotype A allele  
n (%)
G allele  
n (%)A/A n (%) A/G n (%) G/G n (%)
Mexican
Control, n = 215 93 (43.3) 89 (41.4) 33 (15.3) 275 (64.0) 155 (36.0)
Enciso-Vargas et al. (30)
HCV, n = 205 67 (32.7) 104 (50.7) 34 (16.6) 238 (58.0) 172 (42.0)
Brazilian
Control, n = 183 81 (44.3) 67 (36.6) 35 (19.1) 229 (62.5) 137 (37.5)
Danilovic et al. (39)
HCV, n = 112 59 (52.7) 34 (30.3) 19 (17.0) 152 (68.0) 72 (32.0)
Iranian
Control, n = 65 39 (60.0) 17 (26.15) 9 (13.85) 95 (73.07) 35 (26.93)
Sepahi et al. (42)
HCV, n = 65 51 (78.46) 0 (0.0) 14 (21.54) 102 (78.46) 28 (21.54)
Iranian
Control, n = 150 57 (38.0) 52 (34.7) 41 (27.3) 166 (55.3) 134 (44.7) Mohammad Alizadeh 
et al. (59)HBV, n = 51 26 (51.0) 16 (31.4) 9 (17.6) 68 (66.6) 34 (33.4)
Chinese
Control, n = 407 45 (11.0) 179 (44.0) 183 (45.0) 269 (33.0) 545 (67.0)
Gu et al. (34)
HBV, n = 203 24 (12.0) 85 (42.0) 94 (46.0) 133 (26.0) 273 (74.0)
Chinese
Control, n = 145 16 (11.0) 68 (47.0) 61 (42.0) 100 (34.5) 190 (65.5)
Zhang et al. (57)
HBV, n = 172 33 (19.0) 89 (52.0) 50 (29.0) 155 (45.0) 189 (55.0)
Chinese
Control, n = 361 33 (9.14) 177 (49.03)
151 
(41.83)
243 (33.65) 479 (66.35)
Chen et al. (60)
HBV, n = 304 47 (15.46) 125 (41.12)
132 
(43.42)
219 (36.0) 389 (64.0)
Tunisian
Control, n = 358 40 (11.2) 142 (39.7) 176 (49.2) 222 (31.0) 494 (69.0)
Ksiaa et al. (58)HCV hemodialyzed, 
n = 500
77 (15.4) 198 (39.6) 225 (45.0) 352 (35.2) 648 (64.8)
Values are presented in frequencies (%) and genotypes and alleles in number (n). Total alleles were determined considering that each homozy-
gote would contribute two copies of  the allele toward the total fraction, while each heterozygote would only contribute one copy toward the 
total fraction.
Therefore, the +49G allele seems to favor the activation and 
proliferation of T-lymphocyte, while the +49A allele is asso-
ciated with the decrease of T-lymphocyte activation in HBV 
and HCV infections.
In relation to the previously mentioned observations, it has 
been reported that +49 A/G polymorphism plays an impor-
tant role in the expression of the CTLA-4 gene. Individuals 
with the +49 A/A genotype have increased expression of 
CTLA-4 on the cell surface compared with the genotypes 
+49 A/G and +49 G/G (52). In addition, the presence of the 
+49A allele in T-cells increases the interaction with the B7.1 
ligand and increases the inhibitory function of CTLA-4. 
Therefore, the +49G allele may favor the activation and pro-
liferation of T-lymphocytes at a high rate. This implies that 
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the +49G allele can favor viral elimination. In contrast, T-
cells carrying the +49 A/A genotype have significantly lower 
rates of activation compared to T-cells with the +49 G/G ge-
notype (53). These findings illustrate that molecular changes 
in CTLA-4 can modify the ability to control the proliferation 
of T-lymphocytes, promoting the persistence or elimination 
of HBV/HCV infection.
In kind, the +49G allele confers protection for the devel-
opment of  CLD in HBV/HCV infections (11, 12), suggest-
ing inhibition of  CTLA-4 could facilitate control of  these 
pathogens. We previously found that the +49G allele is asso-
ciated with HCV chronic infection but not with the presence 
of  liver cirrhosis in the Mexican population (30). A report 
revealed spontaneous HCV clearance to be higher in pa-
tients carrying the +49G allele (54). The above is supported 
by the natural history of  the infection, where the majority of 
patients with acute infection have progressive chronic liver 
damage, and approximately 20% of  patients develop liver 
cirrhosis (10, 55), highlighting the importance of  the cellular 
immune response in elimination and/or persistence of  HCV 
infection.
Danilovic et al. reported that alleles −319C and +49G 
interfere with the ability to block the immune response of 
CTLA-4, favoring chronic infection with genotype 3 HCV 
in a Brazilian population (39). These findings are consistent 
with our results, where subjects with the −319C/+49G hap-
lotype are associated with genotype 3 infection of  HCV (30). 
Moreover +49G allele has been associated with the risk of 
chronic HCV infection in males (30). Males, compared to 
females, are three to five times more likely to develop HCC. 
This risk can be attributed to the production of  androgens in 
men, while the production of  estrogens provides protection 
against the development of  HCC in women (34). These sex 
differences can be attributed to factors encoded in the sex 
chromosomes, giving rise to differential immune activation 
(56). Male sex is considered an important factor in the pro-
gression and risk of  HCV infection. Another study report 
CTLA-4 polymorphisms have been associated with risk to 
HCV infection in an Iranian population (42). Homozygotes 
with +49 G/G show a persistent infection with HBV (57). 
Furthermore, it has been reported that the +49G allele has 
a protective effect against the development of  HCC, and the 
subjects with the +49A allele have greater susceptibility to 
the development of  HCC in HBV infection (34). The +49G 
allele was also detected more frequently in patients who re-
covered from HBV infection (32). However, another study 
shows no association between the polymorphisms studied 
and spontaneous clearance or persistence of  HCV infection. 
The authors demonstrated that CTLA-4 SNPs (+49GG/
CT60 haplotype) could influence susceptibility to HCV in-
fection in the Tunisian hemodialyzed population (Tables 1 
and 2) (58). A meta-analysis showed that the +49G allele 
can positively influence the elimination of  the virus, while 
the presence of  the +49A allele may increase the risk of 
infection with HBV (61). Accordingly, multiple studies have 
reported that the +49 A/G SNP is associated with HBV and 
HCV infection.
Association of −319 A/G and +49 A/G SNPs 
with SVR
The determination of the seven main genotypes of HCV is 
used as a strong and independent predictor of the sustained 
virological response (SVR) to standard therapy (pegylated 
interferon and ribavirin). Patients with genotypes 2 and 3 re-
spond better to treatment than those infected with HCV ge-
notype 1 (62, 63). The CTLA-4 SNPs have been associated 
with SVR to standard treatment in chronic HCV infection, 
whereas the +49G allele or the −319C/+49G haplotype de-
creases viral load in white patients with HCV genotype 1 
infection (40). Concordantly, the CTLA-4 SNPs were as-
sociated with treatment response in multivariable analysis, 
where the presence of favorable +49GG genotype conferred 
greater rate of response (64). Likewise, female sex can be an 
important factor in response to treatment for chronic HCV 
infection (65). However, in our study, we did not find an as-
sociation with SVR (30), probably due to the low number of 
patients undergoing treatment. Thus, the discrepancy in the 
association studies of CTLA-4 SNPs in HBV/HCV may be 
due to the difference in ethnic background of populations 
studied, as well as biased study designs, influenced by a failure 
to control for important factors such as duration of infection, 
disease severity, co-infections, and specific treatment for HCV 
and HBV infections.
Function of CTLA-4 SNPs on HBV/HCV Infection
Although HBV- and HCV-associated hepatic diseases are not 
determined solely by genetic factors of the host, the CTLA-4 
SNPs offer the basis for the knowledge of the immunomolec-
ular mechanisms involved in viral elimination or the develop-
ment of CLD (Figure 1). The major mechanisms by which 
these SNPs can have a functional effect on the response 
against viral infections can be summarized as follows:
•	 the −319C and +49G alleles, either individually or as a 
haplotype, interfere with the ability to block the immune 
response by CTLA-4 (39)
•	 the −319T/+49A haplotype increases expression of 
CTLA-4 (52)
•	 the −319C, +49G alleles, or the −319C/+49G haplotype 
downregulates CTLA-4 (38, 49) and therefore can be po-
tentiating the T-cell response in individuals with HBV and 
HCV infection
•	 the CTLA-4 ligands CD80 and CD86 may play an impor-
tant role in the development of Th1/Th2 cells (66) and, 
therefore, CTLA-4 SNPs could shift the Th1/Th2 balance
•	 these SNPs are in linkage disequilibrium that, by them-
selves or as haplotypes, may alter CTLA-4 gene expression 
and function (40).
SNP of CTLA4 in viral hepatitis
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Immunotherapy for Viral Infections
The expression of CTLA-4 and other inhibitory receptors 
has been found in virally infected cells of HBV, HCV, and 
human immunodeficiency virus (HIV) patients, and is asso-
ciated with dysfunction of cellular immune response by T-
cells, and an increased viral load. Blockade of the CTLA-4 
pathway in vitro restores the antiviral capacity of exhausted 
T-cells in chronically infected patients (13). The drugs which 
block CTLA-4 are currently in use for cancer patients (67) 
but not for HBV- or HCV-infected patients due to the liver 
damage that can generate the CTLA-4 inhibition (2). It has 
been reported that melanoma patients with HBV or HCV, 
when treated with ipilimumab (human α-CTLA-4), experi-
enced lower viral titers. Patients who did not develop progres-
sive melanoma during treatment with ipilimumab responded 
to immunotherapy and experienced dramatic reductions in 
viral load (68). Another study reports that immunotherapy 
with tremelimumab (human α-CTLA-4 antibody) of HCC 
patients with HCV reduces viral load more than 10 times (in 
10 of 17 patients). It should be noted that the decrease in viral 
loads also correlates with the appearance of HCV mutants 
(69). It is possible that immunotherapy could be the next ther-
apeutic tool to treat chronic HBV or HCV infections. How-
ever, more research is needed to evaluate the side effects and 
determine the safety profile of CTLA-4 blockade in patients 
infected with viral hepatitis.
Conclusion
In conclusion, most studies find −319 C/T SNP in the form 
of +49G/−319C haplotype. This is directly associated with 
SVR and chronic infection in genotype 3 HCV patients but 
not in HCV genotype 1 patients. These patients have the low-
est SVR. This suggests that identifying individuals with the 
+49G/−319C haplotype for treatment may improve prognos-
tication. Taken together, studies of CTLA-4 SNPs in viral 
hepatitis propose that the +49G allele is associated with 
chronic infection (HBV/HCV) but is protective against the 
development of HCC. Therefore, although the +49G allele 
is the most prevalent in chronic infection, it does not mean 
that this allele presents a poor prognosis. The +49G allele 
is also associated with viral elimination and SVR; therefore, 
it can be proposed as a marker of better prognosis in HBV 
and HCV infections. In addition, the knowledge of the role 
of CTLA-4 SNPs in viral hepatitis may assist in the develop-
ment of specific immunotherapy for these infections. None-
theless, more studies are needed to elucidate the implication 
of these SNPs in the pathogenesis and progression, and sus-
ceptibility to HBV and HCV infections.
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